Antioxidant enzyme profile of two clinical isolates of Entamoeba histolytica varying in sensitivity to antiamoebic drugs

Table 4 Percent viability of clinical isolate 980 and 989 after treatment with metronidazole and auranofin

	15 h	24 h	48 h
Percent viability of clinical isolate 980 after treatment with metronidazole
50 μmol/L metronidazole	61.8 ± 0.13	74.12 ± 14.1	70.23 ± 3.66
70 μmol/L metronidazole	53.06 ± 14.1	69.38 ± 3.13	60.68 ± 6.74
90 μmol/L metronidazole	47.31 ± 6.2	26.39 ± 10.7	24.3 ± 14.75
Percent viability of clinical isolate 980 after treatment with auranofin
1 μmol/L auranofin	91.5 ± 0.26	25.17 ± 5.85	12.88 ± 1.63
2 μmol/L auranofin	56.6 ± 5.81	27.92 ± 5.84	0
3 μmol/L auranofin	47.74 ± 7.67	22.41 ± 4.62	0
Percent viability of clinical isolate 989 after treatment with metronidazole
20 μmol/L	-	92.51 ± 2.79	65.22 ± 18.5
30 μmol/L	-	76.11 ± 17.13	25.39 ± 5.33
40 μmol/L	-	54.81 ± 0.57	0
Percent viability of clinical isolate 989 after treatment with auranofin
0.5 μmol/L	-	45.47 ± 0.26	43.01 ± 2.33
1 μmol/L	-	36.63 ± 3.00	19.4 ± 2.95
2 μmol/L	-	29.16 ± 2.95	0

Values are expressed as percent of controls.